Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients

被引：0

作者：

F Passamonti

B Mora

T Giorgino

P Guglielmelli

M Cazzola

M Maffioli

A Rambaldi

M Caramella

R Komrokji

J Gotlib

J J Kiladjian

F Cervantes

T Devos

F Palandri

V De Stefano

M Ruggeri

R Silver

G Benevolo

F Albano

D Caramazza

E Rumi

M Merli

D Pietra

R Casalone

T Barbui

L Pieri

A M Vannucchi

机构：

[1] University of Insubria,Division of Hematology, Department of Clinical and Experimental Medicine

[2] Ospedale di Circolo,Department of Experimental and Clinical Medicine

[3] ASST Sette Laghi,Department of Oncology and Hematology

[4] Institute of Neurosciences,Department of Hematology and BMT Unit

[5] National Research Council of Italy,Malignant Hematology Department

[6] CRIMM-Centro Ricerca e Innovazione delle Malattie Mieloproloiferative,Division of Hematology

[7] Azienda ospedaliera-Universitaria Careggi,Department of Hematology

[8] University of Florence,Department of Oncology and Hematology

[9] Università di Pavia,Department of Oncology and Hematology

[10] University of Milan,Department of Services

[11] ASST Papa Giovanni XXIII,undefined

[12] Department of Oncology and Hematology Ospedale Niguarda Cà Granda,undefined

[13] Moffit Cancer Center,undefined

[14] Stanford University,undefined

[15] Hôpital Saint-Louis et Université Paris Diderot,undefined

[16] Hospital Clínic,undefined

[17] IDIBAPS,undefined

[18] University of Barcelona,undefined

[19] University Hospitals Leuven,undefined

[20] Policlinico S. Orsola-Malpighi,undefined

[21] Institute of Hematology,undefined

[22] Università Cattolica del Sacro Cuore,undefined

[23] Ospedale S. Bortolo,undefined

[24] Weill Cornell Medical College,undefined

[25] Centro Oncologico Ematologico Subalpino (COES),undefined

[26] Department of Oncology and Hematology Università di Bari,undefined

[27] Cytogenetics and Medical Genetics Laboratory,undefined

[28] Ospedale di Circolo,undefined

[29] ASST Sette Laghi,undefined

来源：

Leukemia | 2017年 / 31卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：970 / 973

页数：3

共 50 条

[21] Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis
Gowin, K.
Kosiorek, H.
Dueck, A.
Mascarenhas, J.
Hoffman, R.
Reeder, C.
Camoriano, J.
Tibes, R.
Gano, K.
Palmer, J.
Mesa, R.
LEUKEMIA RESEARCH, 2017, 60 : 31 - 35
[22] Mutational Landscape, Clonal Evolution and Prognostic Effect of Non-Driver Mutations during Disease Progression of Primary Myelofibrosis
Yan, Xin
Xu, Zefeng
Qu, Shiqiang
Qin, Tiejun
Huang, Gang
Xiao, Zhijian
Li, Bing
BLOOD, 2022, 140 : 3965 - 3966
[23] A MULTICENTER STUDY OF PATIENTS WITH NEPHROCALCINOSIS SECONDARY TO MUTATIONS IN THE GENES ENCODING TWO RENAL PROXIMAL TUBULAR PHOSPHATE TRANSPORTERS
Arango Sancho, Pedro
Madariaga Dominguez, Leyre
Ortega, Pedro J.
Gonzalez Rodriguez, Juan David
Aparicio Lopez, Cristina
De Lucas Collantes, Carmen
Blazquez Gomez, Cristina
Angeles Fernandez, Ma
Herrero Goni, Maria
Fraga Rodriguez, Gloria Ma
Espino Hernandez, Maria Del Mar
Garcia Nieto, Victor Manuel
PEDIATRIC NEPHROLOGY, 2023, 38 : S253 - S253
[24] The Impact of Driver Mutations of JAK2, Calr, or MPL in Patients with Myelofibrosis Undergoing Hemopoietic Stem Cell Transplantation
Bacigalupo, Andrea
Pozzi, Sarah
van Lint, Maria Teresa
Bregante, Stefania
Barosi, Gianni
Pietra, Daniela
Rumi, Elisa
Milanesi, Chiara
Cazzola, Mario
BLOOD, 2015, 126 (23)
[25] Final Analysis of a Multicenter Pilot Phase 2 Study of Ruxolitinib and Danazol in Patients with Myelofibrosis
Gowin, Krisstina L.
Kosiorek, Heidi E.
Dueck, Amylou Constance
Mascarenhas, John
Hoffman, Ronald
Reeder, Craig B.
Camoriano, John
Fauble, Veena
Tibes, Raoul
Gano, Katherine
Ghurye, Vineta
Koenig, Patricia
Mesa, Ruben A.
BLOOD, 2015, 126 (23)
[26] NON-DRIVER MUTATIONS IDENTIFIED BY A 190-GENE NEXT GENERATION SEQUENCING PANEL IN PATIENTS WITH PRIMARY MYELOFIBROSIS AND POST-POLYCYTHAEMIC/ESSENTIAL THROMOCYTHAEMIA MYELOFIBROSIS
Li, B.
Xu, Z.
Qin, T.
Zhang, Y.
Liu, J.
Xiao, Z.
HAEMATOLOGICA, 2017, 102 : 546 - 547
[27] Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis: A Phase 2 Study
Harrison, Claire
Garcia, Jacqueline S.
Mesa, Ruben
Somervaille, Tim
Ritchie, Ellen K.
Komrokji, Rami S.
Pemmaraju, Naveen
Jamieson, Catriona
Papadantonakis, Nikolaos
Foran, James M.
O'Connell, Casey L.
Verstovsek, Srdan
Jung, Paul
Holes, Leanne
Masud, Abdullah
Harb, Jason
Hutti, Jessica E.
Prchal, Josef T.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S325 - S325
[28] Synergistic effect of concurrent high molecular risk mutations and lower JAK2 mutant variant allele frequencies on prognosis in patients with myelofibrosis-insights from a multicenter study
Wang, Yu-Hung
Wei, Chao-Hung
Lin, Chien-Chin
Gurnari, Carmelo
Awada, Hussein
Benajiba, Lina
Daltro de Oliveira, Rafael
Soret-Dulphy, Juliette
Cassinat, Bruno
Zucenka, Andrius
Mosquera Orgueira, Adrian
Yuan, Chang-Tsu
Lee, Sze-Hwei
Yao, Chi-Yuan
Gurashi, Kristian
Hou, Hsin-An
Batta, Kiran
Perez Encinas, Manuel Mateo
Chou, Wen-Chien
Maciejewski, Jaroslaw P.
Wiseman, Daniel H.
Kiladjian, Jean-Jacques
Tien, Hwei-Fang
LEUKEMIA, 2024, : 144 - 154
[29] EVIDENCE BASED USE OF ERYTRHOPOIETIN IN PATIENTS WITH AUTOIMMUNE HEMOLYTIC ANEMIA: A MULTICENTER INTERNATIONAL STUDY
Fattizzo, B.
Levati, G.
Languille, L.
Mauro, F. R.
Jilma, B.
Patriarca, A.
Hill, A.
Berentsen, S.
Michel, M.
Barcellin, W.
HAEMATOLOGICA, 2019, 104 : 26 - 27
[30] A New Prognostic Scoring System for Primary Myelofibrosis Based on a Study of the International Working Group for Myelofibrosis Research and Treatment
Cervantes, Francisco
Dupriez, Brigitte
Pereira, Arturo
Passamonti, Francesco
Reilly, John T.
Morra, Enrica
Vannucchi, Alessandro
Mesa, Ruben A.
Demory, Jean-Loup
Barosi, Giovanni
Rumi, Elisa
Tefferi, Ayalew
BLOOD, 2008, 112 (11) : 245 - 245

← 1 2 3 4 5 →